Publications by authors named "Joao Pedro N Lubianca"
Key Points: The effect of sodium-glucose cotransporter 2 inhibitors in preventing kidney outcomes in populations at lower risk of kidney disease remains uncertain. Pooled data from randomized controlled trials show that sodium-glucose cotransporter 2 inhibitors prevent kidney outcomes across the spectrum of kidney disease risk.
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with CKD at high risk of adverse outcomes.
Article Synopsis
- This study evaluated the impact of SGLT2 inhibitors on heart-related health outcomes and mortality rates, focusing on different kidney disease risk groups (KDIGO and UACR).
- Researchers analyzed data from 14 large randomized trials involving over 97,000 participants and found that SGLT2 inhibitors significantly reduced major cardiovascular events and all-cause mortality, with particular benefits noted in high-risk kidney disease groups.
- The findings suggest that SGLT2 inhibitors can improve cardiovascular health, especially in patients with severe kidney disease.
Background: SGLT2 inhibitors have shown to reduce clinically meaningful kidney outcomes in individuals with chronic kidney disease at high risk for adverse outcomes. The effect of these agents in preventing clinically meaningful kidney outcomes in populations at lower risk remain uncertain. We aim to evaluate the effect of SGLT2 inhibitors on kidney outcomes across the Kidney Disease: Improving Global Outcomes (KDIGO) classification and urinary albumin-to-creatinine ratio (UACR) levels.
View Article and Find Full Text PDF